Management of Acute Cholangitis
The cornerstone of acute cholangitis management is immediate biliary drainage combined with appropriate antimicrobial therapy, with the timing and method of drainage determined by disease severity. 1, 2
Initial Assessment and Diagnosis
Begin with ultrasound as the first-line imaging modality 1, 3. Look for:
- Dilated intra- and extra-hepatic bile ducts
- Thickened bile duct walls
- Intraluminal stones or sludge
If ultrasound is equivocal, proceed to CT with IV contrast or MRCP. Consider endoscopic ultrasound (EUS) or ERCP for definitive diagnosis and therapeutic intervention 1.
Severity-Based Treatment Algorithm
Mild (Grade I) Acute Cholangitis
For immunocompetent, non-critically ill patients:
- Antibiotics: Amoxicillin/clavulanate 2g/0.2g IV q8h 1
- Alternative (beta-lactam allergy): Eravacycline 1 mg/kg q12h or Tigecycline 100 mg loading dose then 50 mg q12h 1
- Duration: 4 days if adequate source control is achieved 1
- Biliary drainage: Most respond to antibiotics alone; consider drainage only if no response to initial medical treatment 2, 4, 5
Moderate (Grade II) Acute Cholangitis
For patients at risk of clinical deterioration:
- Immediate ERCP for biliary drainage (unless contraindicated) 2
- Antibiotics: Same as mild cases if immunocompetent
- For critically ill/immunocompromised: Piperacillin/tazobactam 6g/0.75g loading dose, then 4g/0.5g q6h or 16g/2g continuous infusion 1
- Duration: 4 days for immunocompetent patients; up to 7 days for immunocompromised/critically ill based on clinical response 1
Severe (Grade III) Acute Cholangitis
For patients with organ dysfunction:
- Immediate resuscitation: Respiratory and circulatory support as needed 2, 4
- Urgent biliary drainage: ERCP as soon as hemodynamically stable 2, 4
- Broad-spectrum antibiotics within 1 hour if septic shock present 6:
- Meropenem 1g q6h by extended infusion or continuous infusion, OR
- Doripenem 500 mg q8h by extended infusion, OR
- Imipenem/cilastatin 500 mg q6h by extended infusion, OR
- Eravacycline 1 mg/kg q12h 1
- Duration: Up to 7 days based on clinical response and inflammation markers 1
Special Considerations for High-Risk Patients
If inadequate/delayed source control OR high risk for ESBL-producing Enterobacterales:
- Ertapenem 1g q24h, OR
- Eravacycline 1 mg/kg q12h 1
Healthcare-associated cholangitis (previous biliary instrumentation, stenting, or PTBD):
- Use 4th-generation cephalosporins with adjustments per antibiogram 6
- Consider anti-enterococcal coverage 3
Biliary Drainage Methods
The choice depends on severity, local expertise, and anatomical considerations 1:
- ERCP (first-line for most cases)
- Percutaneous transhepatic cholangiography (PTC) (if ERCP fails or contraindicated)
- Surgical drainage (rarely needed; reserved for failed endoscopic/percutaneous approaches)
Critical Pitfalls to Avoid
- Do not delay biliary drainage in moderate/severe cases - antibiotics alone are insufficient when obstruction persists 2, 4
- Do not continue antibiotics beyond 7 days without reassessment - patients with persistent symptoms warrant diagnostic investigation for inadequate source control 1
- Do not use anaerobic coverage routinely unless biliary-enteric anastomosis is present 3
- In severe sepsis/shock, start antibiotics within 1 hour - do not delay for diagnostic studies 6
Duration of Antibiotic Therapy
The 2024 Italian guidelines provide the most current recommendations 1:
- 4 days for immunocompetent, non-critically ill patients with adequate source control
- Up to 7 days for immunocompromised or critically ill patients, adjusted based on clinical response and inflammatory markers
- Recent evidence suggests even shorter courses (1-3 days) may be adequate post-drainage 7, though this requires further validation
Multidisciplinary Management
For Grade III cholangitis or patients with risk factors for resistant organisms, involve infectious disease specialists and antibiotic stewardship teams early 2. Adjust empiric therapy based on bile and blood cultures when available 1, 6.